KNSA vs. PCRX, SYRE, LGND, VRNA, IRWD, PIRS, DCPH, COLL, GMTX, and ABCL
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Ligand Pharmaceuticals (LGND), Verona Pharma (VRNA), Ironwood Pharmaceuticals (IRWD), Pieris Pharmaceuticals (PIRS), Deciphera Pharmaceuticals (DCPH), Collegium Pharmaceutical (COLL), Gemini Therapeutics (GMTX), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
Pacira BioSciences received 643 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 71.73% of users gave Pacira BioSciences an outperform vote while only 64.06% of users gave Kiniksa Pharmaceuticals an outperform vote.
Pacira BioSciences has a net margin of 6.22% compared to Pacira BioSciences' net margin of 2.78%. Kiniksa Pharmaceuticals' return on equity of 12.81% beat Pacira BioSciences' return on equity.
Pacira BioSciences has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.
Pacira BioSciences has higher revenue and earnings than Kiniksa Pharmaceuticals. Pacira BioSciences is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 6.6% of Pacira BioSciences shares are owned by insiders. Comparatively, 54.2% of Kiniksa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Pacira BioSciences currently has a consensus price target of $49.50, indicating a potential upside of 88.00%. Kiniksa Pharmaceuticals has a consensus price target of $30.00, indicating a potential upside of 67.79%. Given Kiniksa Pharmaceuticals' higher probable upside, analysts plainly believe Pacira BioSciences is more favorable than Kiniksa Pharmaceuticals.
In the previous week, Kiniksa Pharmaceuticals had 24 more articles in the media than Pacira BioSciences. MarketBeat recorded 27 mentions for Kiniksa Pharmaceuticals and 3 mentions for Pacira BioSciences. Kiniksa Pharmaceuticals' average media sentiment score of 0.83 beat Pacira BioSciences' score of 0.38 indicating that Pacira BioSciences is being referred to more favorably in the media.
Summary
Pacira BioSciences beats Kiniksa Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Kiniksa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
Related Companies and Tools
